ArticleFrontiers in immunology2026
Identification and dual-center histological validation of EMT core genes in chronic rhinosinusitis with nasal polyps: an integrated multi-cohort transcriptomic and single-cell analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is highly heterogeneous. Epithelial-mesenchymal transition (EMT) is implicated in mucosal remodeling and postoperative recurrence, yet robust EMT biomarkers consistently validated across cohorts and by histology are lacking. Methods: RNA-seq data from a Chongqing (CQ) cohort were integrated with multiple GEO datasets. After batch-effect correction, differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed. EMT-related candidates were obtained by intersecting results with the MSigDB EMT gene set. Core genes were identified using multi-algorithm feature selection (LASSO, SVM-RFE, and random forest). A three-gene model was constructed and externally validated. Single-cell transcriptomic data were used to define cellular sources of core genes, and immune infiltration and pathway activity were assessed. Regulatory networks (TF/miRNA) and compound-disease associations were predicted. Finally, expression was validated in dual-center clinical cohorts (CQ and Liaoning [LN]) by qRT-PCR and immunohistochemistry/immunofluorescence, and associations with SNOT-22 and the eosinophilic endotype were evaluated. Results: Twenty-five EMT-related candidate genes were identified. Multi-algorithm intersection highlighted SPP1, PTHLH, and IGFBP3 as EMT core genes, consistently upregulated in the training set, the external validation dataset, and dual-center specimens. The three-gene model achieved AUCs of 0.944-0.991 in the training set and 0.888-0.938 in the external validation dataset. Single-cell mapping indicated that SPP1 was primarily derived from myeloid cells, PTHLH from epithelial cells, and IGFBP3 enriched in fibroblasts. Higher core-gene expression was associated with increased immune infiltration and activation of TGF-β, hypoxia/glycolysis, and inflammation-related pathways. Histology supported EMT-associated phenotypic changes in CRSwNP, with stronger signals in the eosinophilic endotype. In CQ and LN cohorts, core-gene expression correlated with SNOT-22 (Spearman r = 0.402-0.569, P ≤ 0.021). Conclusions: SPP1, PTHLH, and IGFBP3 are robustly validated EMT core genes in CRSwNP across multiple cohorts and dual-center histology, closely linked to immune microenvironment alterations and mucosal remodeling. These genes represent robust EMT-associated candidate biomarkers for future stratification efforts and mechanistic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.